Shares of Bionano Genomics (BNGO) plummeted 5.32% in intraday trading following the release of the company's first-quarter 2025 financial results and full-year revenue guidance. The sharp decline suggests that investors were not impressed with the company's performance and future prospects.
Bionano reported Q1 revenue of $6.5 million, with a gross margin of 46%. However, the company's operating expenses remained high at $11.4 million, with adjusted operating expenses of $8.5 million. These figures indicate that Bionano is still struggling to achieve profitability, which likely contributed to the negative market reaction.
Adding to investor concerns, Bionano provided a full-year 2025 revenue outlook of $26-30 million. This guidance may have fallen short of market expectations, potentially signaling slower growth than anticipated. The combination of high operating expenses and a possibly conservative revenue forecast appears to have shaken investor confidence, leading to the significant drop in stock price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.